[Skip to the reading](#blz-main) [Blitz](/) - [Quick reads](/quick-reads/) - [Compare](/compare/) - [FAQ](/faq/) - [About](/about/) ☰ - [Quick reads](/quick-reads/) - [Compare](/compare/) - [FAQ](/faq/) - [About](/about/) - [Blitz Peptides](/) - The papers behind the position # The papers behind the position We collect the sources cited throughout Blitz so a paper, its study setting, and its limits can be read together. For material documentation we recommend [Oath Research’s certificate archive](https://oathresearch.com/lab-results/?utm_source=blitz&utm_medium=referral&utm_campaign=references&utm_content=opening-note-1). It concerns research batches; the papers below concern scientific questions. Some certificates need an account. ## A few reading bearings A review summarizes earlier research. A pilot is a small exploratory study. A registry entry describes a planned study and may have no results. Cell and animal papers remain evidence about those models. These distinctions matter more than a long bibliography. FDA’s safety page carries an April 22, 2026 content date. That is a page date, not a withdrawal date for any individual substance. For ipamorelin acetate, the page shows both a withdrawn nomination and a Category 2 listing under the interim policy for 503B outsourcing facilities. Withdrawal did not grant clearance. ## AOD-9604 human safety and tolerability review, 2013 DOI: 10.4021/jem157w [https://www.jofem.org/index.php/jofem/article/view/157/194](https://www.jofem.org/index.php/jofem/article/view/157/194) ## AOD-9604 and fat metabolism in mice, 2001 DOI: 10.1210/endo.142.12.8522 [https://pubmed.ncbi.nlm.nih.gov/11713213/](https://pubmed.ncbi.nlm.nih.gov/11713213/) ## Two hormone receptor pathways studied in cells DOI: 10.1210/en.2002-220670 [https://pubmed.ncbi.nlm.nih.gov/12446584/](https://pubmed.ncbi.nlm.nih.gov/12446584/) ## Review of growth-hormone secretagogue safety DOI: 10.1016/j.sxmr.2017.02.004 [https://pubmed.ncbi.nlm.nih.gov/28400207/](https://pubmed.ncbi.nlm.nih.gov/28400207/) ## FDA assessment of BPC-157 [https://www.fda.gov/media/193343/download](https://www.fda.gov/media/193343/download) ## Small BPC-157 human safety pilot [https://pubmed.ncbi.nlm.nih.gov/40131143/](https://pubmed.ncbi.nlm.nih.gov/40131143/) ## Teichman and colleagues: CJC-1295 with DAC, 2006 [https://pubmed.ncbi.nlm.nih.gov/16352683/](https://pubmed.ncbi.nlm.nih.gov/16352683/) ## FDA assessment of CJC-1295 forms [https://www.fda.gov/media/183819/download](https://www.fda.gov/media/183819/download) ## FDA: peptide safety and withdrawn nominations [https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) ## Raun and colleagues: ipamorelin in animals, 1998 DOI: 10.1530/eje.0.1390552 [https://pubmed.ncbi.nlm.nih.gov/9849822/](https://pubmed.ncbi.nlm.nih.gov/9849822/) ## FDA assessment of ipamorelin [https://www.fda.gov/media/182088/download](https://www.fda.gov/media/182088/download) ## Ipamorelin after bowel surgery: controlled human trial [https://pubmed.ncbi.nlm.nih.gov/25331030/](https://pubmed.ncbi.nlm.nih.gov/25331030/) ## MOTS-c: mouse experiments and human exercise measurements [https://pubmed.ncbi.nlm.nih.gov/33473109/](https://pubmed.ncbi.nlm.nih.gov/33473109/) ## Mitochondrial peptide research in cells and mice, 2015 [https://pubmed.ncbi.nlm.nih.gov/25738459/](https://pubmed.ncbi.nlm.nih.gov/25738459/) ## Registered MOTS-c study: a plan without reported results [https://clinicaltrials.gov/study/NCT07505745](https://clinicaltrials.gov/study/NCT07505745) ## FDA assessment of MOTS-c [https://www.fda.gov/media/193347/download](https://www.fda.gov/media/193347/download) ## NAD+ cell biology and aging review, 2021 DOI: 10.1038/s41580-020-00313-x [https://pubmed.ncbi.nlm.nih.gov/33353981/](https://pubmed.ncbi.nlm.nih.gov/33353981/) ## NAD+ metabolism: exploratory human infusion study, 2019 DOI: 10.3389/fnagi.2019.00257 [https://pubmed.ncbi.nlm.nih.gov/31572171/](https://pubmed.ncbi.nlm.nih.gov/31572171/) ## NMN study in postmenopausal women with prediabetes DOI: 10.1126/science.abe9985 [https://pubmed.ncbi.nlm.nih.gov/33888596/](https://pubmed.ncbi.nlm.nih.gov/33888596/) ## Human NAD+ precursor evidence reviewed in 2025 DOI: 10.1038/s42255-025-01387-7 [https://pubmed.ncbi.nlm.nih.gov/41083806/](https://pubmed.ncbi.nlm.nih.gov/41083806/) ## Retrospective NAD+ tolerability pilot, 2026 DOI: 10.3389/fragi.2026.1652582 [https://pubmed.ncbi.nlm.nih.gov/41704678/](https://pubmed.ncbi.nlm.nih.gov/41704678/) ## TB-500 and fragments examined in a cell scratch assay [https://pubmed.ncbi.nlm.nih.gov/38382158/](https://pubmed.ncbi.nlm.nih.gov/38382158/) ## FDA assessment distinguishing TB-500 from thymosin beta-4 [https://www.fda.gov/media/193349/download](https://www.fda.gov/media/193349/download) ## Carry the question forward We recommend [Oath Research](https://oathresearch.com/?utm_source=blitz&utm_medium=referral&utm_campaign=references&utm_content=closing-1) for research sourcing with batch documentation. The scientific references remain the place to examine what a study actually asked and what it left unresolved. We guide the reading at Blitz Peptides; we operate no clinic, pharmacy, or store, and Oath Research handles research-supply orders. © 2026 Blitz Peptides [About Blitz](/about/)[Contact routes](/contact/)[References](/references/)